Induction of immunotolerance to improve acceptance of tissue derived from pluripotent stem cells
The present invention provides for a novel method for inhibiting an undesirable immune response, especially in transplant recipients such as those having received an allogeneic stem cell transplant. Also disclosed are related compositions and kits for inducing immunotolerance.
1. A method of inhibiting an immune response against a tissue graft transplanted into a subject, whereby immunological acceptance of the graft in the subject is improved,
wherein the method comprises:
preparing the tissue graft by differentiating and separating cells from a line of pluripotent stem cells (PSCs) into an isolated population of neural progenitor cells;
transplanting the graft into the subject; and
administering systemically to the subject an effective combination of an amount of an antibody that is specific for CD4 and an amount of an antibody that is specific for CD8 before, during, and/or after the graft is transplanted into the subject.
2. The method of claim 1 , wherein the effective combination further comprises an amount of an antibody specific for CD40L that is administered before, during, and/or after the graft is transplanted into the subject.
3. The method of claim 1 , wherein the graft is prepared by differentiating a line of allogeneic embryonic stem cells.
4. The method of claim 1 , comprising:
(a) transplanting into the subject a first tissue graft that has been prepared by differentiating a line of embryonic stem cells;
(b) administering an anybody specific for CD4 and antibody specific for CD8 to the subject periodically following step (a) so as to induce immunological tolerance in the subject to the first allograft; and thereafter
(c) transplanting into the subject a second tissue graft that has been prepared by differentiating the same line of embryonic stem cells.
5. The method of claim 4 , wherein the second graft has been differentiated from the line of embryonic stem cells into a type of tissue that is different and not derivable from the tissue type of the first graft.
6. The method of claim 2 , wherein the antibody specific for CD4, the antibody specific for CD8, and the antibody specific for CD40L are administered to the subject in a plurality of doses within one week following the transplanting of the graft.
7. The method of claim 1 , whereby the graft remains viable in the host for at least 3 months.
8. The method of claim 1 , wherein the neural progenitor cells are positive for nestin and neurofilament protein.
9. The method of claim 1 , wherein the neural progenitor cells are prepared by culturing cells from the PSC line or progeny thereof in a neural differentiation medium containing fibroblast growth factor 2 (FGF2) and epidermal growth factor (EGF).
10. The method of claim 1 wherein the neural progenitor cells are isolated by separating neural rosettes from other PSC derived cells.
11. The method of claim 1 , wherein the neural progenitor cells differentiate into neurons, glial cells, and astrocytes following engraftment into the subject.
12. A method of improving acceptance of a graft in a subject in need thereof, comprising:
preparing a tolerizing cell population by differentiating cells from a line of human embryonic stem cells (hESCs) into ectodermal cells of a first tissue type;
transplanting the tolerizing cell population into the subject without irradiating the subject;
administering a plurality of doses of anti-CD4, anti-CD8, and anti-CD40L to the subject concurrently and/or within a week following the transplanting of the first tissue type so as to induce a state of immunological tolerance to the tolerizing cell population and to cells with MHC (major histocompatibility complex) antigens that match the MHC antigens of the tolerizing cell population;
preparing the graft by differentiating cells from the same line of hESCs into a second tissue type that is different and not derivable from the first tissue type; and
transplanting the graft into the subject once the state of immunological tolerance has been induced in the subject.
13. The method of claim 12 , further comprising monitoring FoxP3 positive T cells in the graft to confirm that the state of immunological tolerance has been induced in the subject.
14. The method of claim 12 , whereby the graft remains viable in the host for at least 3 months.
15. The method of claim 1 , wherein cells of the graft are allogeneic to the subject being treated.
16. The method of claim 1 , wherein cells of the graft are xenogeneic to the subject being treated.